KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Amortization of Deferred Charges (2019 - 2021)

Edwards Lifesciences (EW) has 3 years of Amortization of Deferred Charges data on record, last reported at $7.1 million in Q4 2021.

  • For Q4 2021, Amortization of Deferred Charges fell 5.33% year-over-year to $7.1 million; the TTM value through Dec 2021 reached $28.5 million, up 1.06%, while the annual FY2021 figure was $28.5 million, 1.06% up from the prior year.
  • Amortization of Deferred Charges reached $7.1 million in Q4 2021 per EW's latest filing, roughly flat from $7.1 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $7.5 million in Q4 2020 and bottomed at $5.7 million in Q1 2019.
  • Average Amortization of Deferred Charges over 3 years is $6.8 million, with a median of $7.0 million recorded in 2019.
  • Peak YoY movement for Amortization of Deferred Charges: rose 17.54% in 2020, then decreased 5.33% in 2021.
  • A 3-year view of Amortization of Deferred Charges shows it stood at $6.6 million in 2019, then rose by 13.64% to $7.5 million in 2020, then fell by 5.33% to $7.1 million in 2021.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $7.1 million in Q4 2021, $7.1 million in Q3 2021, and $7.0 million in Q2 2021.